Stockreport

Merck's Keytruda Gets Priority Review in Difficult Lung Cancer [Yahoo! Finance News]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on [Read more]